Online citations, reference lists, and bibliographies.
← Back to Search

Chemotherapy For Malignant Pleural Mesothelioma: Past, Present And Future

A. Scherpereel
Published 2017 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Purpose of ReviewThis paper aims to propose an update on therapeutic medical options for malignant pleural mesothelioma (MPM).Recent FindingsFor 13 years, the standard of care in MPM patients has been cisplatin/pemetrexed chemotherapy. Recently, the Cis/Pem/bevacizumab triplet emerged as a new option for MPM patients eligible for bevacizumab, and not as a candidate for multimodality therapy trials, as validated by the last NCCN and French guidelines. Immunotherapy is also emerging as a promising option on its own or in combination with first-line Cis/Pem, or even as a valuable alternative to chemotherapy, radical surgery, and multimodality strategies.SummaryTargeted therapies and immunotherapy are new promising treatments in MPM as single agents or in combination with chemotherapy. However, the key challenge remains to find reliable predictive biomarkers for these innovative, exciting, and expensive treatments to select the best patients for each strategy. After years of nihilism and negative trials, numerous therapeutic strategies can now be offered to mesothelioma patients and the future looks brighter.
This paper references
10.1183/09031936.00037310
Valproate–doxorubicin: promising therapy for progressing mesothelioma. A phase II study
A. Scherpereel (2010)
10.1126/scitranslmed.3008639
Merlin Deficiency Predicts FAK Inhibitor Sensitivity: A Synthetic Lethal Relationship
I. Shapiro (2014)
10.1016/S1470-2045(13)70125-6
Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
W. Buikhuisen (2013)
10.5306/wjco.v7.i2.135
Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment.
I. Marchesi (2016)
10.1001/jamaoncol.2016.3049
Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1–Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial
P. Szlosarek (2017)
10.1371/journal.pone.0121071
Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)
S. Cedrés (2015)
10.1016/j.lungcan.2014.03.006
Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma.
M. Zauderer (2014)
10.1126/scitranslmed.3006941
Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression
R. Hassan (2013)
10.1038/bjc.2013.368
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
G. Ceresoli (2013)
10.3978/j.issn.2072-1439.2013.11.28
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.
N. van Zandwijk (2013)
10.1038/ng.3520
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
R. Bueno (2016)
10.1093/annonc/mdq173
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
R. Stahel (2010)
10.1016/j.lungcan.2013.11.026
A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.
C. Cao (2014)
10.6004/JNCCN.2016.0087
NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.
D. Ettinger (2016)
10.2174/1871520611313020014
The role of mesothelin in tumor progression and targeted therapy.
Zhewei Tang (2013)
Immune checkpoint blockade in malignant mesothelioma : a novel therapeutic strategy against a deadly disease ?
L Calabrò (2014)
10.1158/0008-5472.CAN-14-1328
Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma.
Jinfei Xu (2014)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1183/13993003.00319-2017
Malignant pleural mesothelioma: new treatments, new hopes?
A. Scherpereel (2017)
Immune checkpoint blockade in malignant mesothelioma: a novel therapeutic strategy against a deadly disease? Oncoimmunology
L Calabrò (2014)
10.1016/j.lungcan.2011.08.011
Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
P. Zucali (2012)
10.1158/1078-0432.CCR-15-2133
Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy
D. Sterman (2016)
10.1016/j.lungcan.2012.05.111
A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.
J. Dowell (2012)
10.1164/rccm.201508-1573OC
Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma.
R. Cornelissen (2016)
10.1158/1078-0432.CCR-14-0804
Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
R. Hassan (2014)
10.1038/nm.3947
Loss of BAP1 function leads to EZH2-dependent transformation
Lindsay M. LaFave (2015)
10.3109/9781439802014-13
Malignant mesothelioma.
B. Robinson (2005)
10.1200/JCO.2011.41.5869
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
H. Kindler (2012)
10.1200/JCO.2006.09.9887
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
J. Jassem (2008)
10.1016/S1470-2045(17)30169-9
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
E. Alley (2017)
10.1097/JTO.0b013e31817c73d6
Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program
A. Santoro (2008)
10.1183/09031936.00063109
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
10.1016/j.jtho.2016.01.014
A Randomized Phase II Study Adding Axitinib to Pemetrexed‐Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single‐Center Trial Combining Clinical and Translational Outcomes
W. Buikhuisen (2016)
10.1016/j.athoracsur.2016.08.071
Extended Pleurectomy-Decortication-Based Treatment for Advanced Stage Epithelial Mesothelioma Yielding a Median Survival of Nearly Three Years.
J. Friedberg (2017)
10.1093/annonc/mdv199
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
P. Baas (2015)
10.1016/S1556-0864(15)30351-8
Pemetrexed Alone or in Combination with Cisplatin in Previously Treated Malignant Pleural Mesothelioma: Outcomes from a Phase IIIB Expanded Access Program
P. Jänne (2006)
10.1016/j.jtcvs.2015.09.129
Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma.
M. D. de Perrot (2016)
10.1097/JTO.0000000000000471
High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma
Masaki Nasu (2015)
Sculier for the European Lung Cancer Working Party ( ELCWP ) . Valproate - doxorubicin : effective therapy for progressing mesothelioma . A phase II study
T Scherpereel (2014)
10.1016/S0140-6736(15)01238-6
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
G. Zalcman (2016)
10.1097/JTO.0000000000000177
B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis
A. Mansfield (2014)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar